Why Establishment Labs Holdings (ESTA) is back on investors’ radar

Establishment Labs Holdings (ESTA) recently reported accelerating revenue growth, higher full-year sales guidance, and improving profitability metrics, with management also outlining an expected path to cash-flow positivity in the second half of 2026.

At a share price of US$72.19, the stock has seen short term momentum build, with a 7 day share price return of 9.78% and a 30 day gain of 7.60%, while the 90 day share price return is down 5.01% and the 1 year total shareholder return is 97.13%. This suggests investors have reacted positively to the stronger revenue trends and raised guidance.

If the renewed interest in Establishment Labs has you looking beyond a single stock, this could be a good moment to broaden your search and uncover 20 top founder-led companies

With revenue growing at 21.9% annually and the stock up 97.13% over the past year, the key question now is whether ESTA still trades below its estimated worth, or if the market is already pricing in future growth.

Most Popular Narrative: 5% Undervalued

The most followed narrative pegs Establishment Labs Holdings' fair value at $76, slightly above the last close of $72.19, and anchors that view in specific revenue and margin assumptions.

The bearish analysts expect earnings to reach $32.3 million (and earnings per share of $1.03) by about May 2029, up from $43.7 million of losses today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as $81.1 million.

Want to understand why this narrative supports a higher fair value than today's share price? Revenue growth, margin expansion and a demanding future earnings multiple sit at the heart of the model. Curious how those moving parts are combined into one number investors keep referring to? The full narrative lays out each assumption in black and white.

Result: Fair Value of $76 (UNDERVALUED)

However, there are still clear risks, including execution doubts around profitability and concerns that sector volatility and tighter valuation assumptions could limit how far the narrative stretches.

Another way to look at valuation

The narrative fair value of US$76 leans on long term earnings forecasts and a high future P/E of about 97x. By contrast, today’s P/S of 9.2x sits well above the US Medical Equipment industry at 2.7x and a fair ratio of 4.7x. This points to meaningful valuation risk if sentiment cools.

For a closer look at what this pricing gap could mean for upside and downside, and how it compares across peers, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Seeing both enthusiasm and caution in this story, it makes sense to look at the underlying data now and decide where you stand, then weigh the 2 key rewards and 1 important warning sign

Looking for more investment ideas?

If ESTA has sharpened your focus, do not stop here. Broaden your watchlist now so you are not late to the next opportunity.

• Target higher quality potential by scanning for companies that pair strong fundamentals with attractive pricing using the 49 high quality undervalued stocks
• Prioritize resilience and support peace of mind by checking stocks that pass strict financial health filters in the solid balance sheet and fundamentals stocks screener (46 results)
• Spot opportunities others might overlook by reviewing the screener containing 21 high quality undiscovered gems before they reach broader attention

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.